Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire

Reis, Abílio; Twiss, James; Vicente, Margarida; Gonçalves, Fabienne; Carvalho, L.; Meireles, J.; Melo, Alzira; McKenna, Stephen P.; Almeida, Luís

doi:10.1186/s12955-016-0513-8

Cited by 8 publications

(6 citation statements)

References 36 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It includes targeted evaluation of PH-specific symptomatology and activities that allows a better characterization of HRQoL in the PH population and includes an additional domain specifically aimed at assessing overall QoL. CAMPHOR was carefully developed and validated for use in PH populations with its content derived directly from patients and, thus, it was widely used over the past decade and is currently validated for use in several countries [ 12 , 14 – 17 ]. More recently, other PROMs, like emPHasis-10 [ 18 ] and PAH-SYMPACT® [ 19 ], have also been developed to allow adequate collection of patient-reported information on health status, but without the capacity to actually evaluate QoL.…”

Section: Introductionmentioning

confidence: 99%

Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study

Reis

Santos

Vicente

et al. 2018

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Background Health-related quality of life (HRQoL) impairment is common in pulmonary hypertension (PH), but its clinical predictors are not well established. This study aims to characterize the HRQoL of patients with pulmonary arterial hypertension (PAH) and other precapillary forms of PH (pcPH) and to explore its clinical correlates. Materials and Methods A cross-sectional, observational study of patients with documented PAH and other forms of pcPH. Patients completed two patient-reported outcome measures (PROM): Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) and Nottingham Health Profile (NHP). Clinical characteristics were retrieved from electronic medical records. Results Mean CAMPHOR and NHP scores for the study population were indicative of a moderate HRQoL impairment. Patients in World Health Organisation Functional Classes (WHO FC) III/IV showed significantly worse HRQoL. The main clinical correlates of HRQoL were WHO FC, 6-minute walking distance (6MWD), and Borg dyspnoea index. Overall quality of life (QoL), assessed through CAMPHOR's QoL domain, showed patterns comparable to HRQoL measured by both instruments. Conclusions HRQoL, measured by two different PROMs, is impaired in Portuguese patients with PAH and other forms of pcPH, particularly in patients with increased disease severity. WHO FC, 6MWD, and Borg dyspnoea index are highly correlated with HRQoL and QoL.

show abstract

Section: Introductionmentioning

confidence: 99%

Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study

Reis

Santos

Vicente

et al. 2018

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

“…Whilst this study has a number of strengths, we acknowledge that although patient characteristics were similar to those of well-published PAH cohorts, data from this study originate from a single pulmonary hypertension centre and may therefore be subject to bias. CAMPHOR has also received criticism for being more time intensive than other available pulmonary hypertension QOL measures, however remains the most validated with adaption for use in, but not limited to, the: United States, 39 Australia/New Zealand, 40 Portugal, 41 Germany, 42 Netherlands, 43 Poland, 44 Brazil, 45 Croatia, 46 French/English Canada 47 and Columbia. 48 This provides plentiful opportunity for the external validation of MCID estimates to assess their robustness which is unafforded by other measures at present.…”

Section: Discussionmentioning

confidence: 99%

A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension

et al. 2021

View full text Add to dashboard Cite

Several patient-reported outcome measures have been developed to assess health status in pulmonary arterial hypertension (PAH). The required change in instrument scores needed, to be seen as meaningful to the individual, however remain unknown. We sought to identify minimal clinically important differences (MCIDs) in the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) and to validate these against objective markers of functional capacity. MCIDs were established from a discovery cohort (n = 129) of consecutive incident cases of idiopathic PAH with CAMPHOR scores recorded at treatment-naÃ¯ve baseline and 6 â 9 months following PAH therapy. An independent validation cohort (n = 87) was used to verify MCIDs. Concurrent measures of functional capacity relative to CAMPHOR scores were collected. MCIDs were derived using anchor- and distributional-based approaches. In the discovery cohort, mean (SD) age was 54.4 (16.4) years and 64% were female. Most patients (63%) were treated with sequential PAH therapy. Baseline CAMPHOR scores were: Symptoms, 12 (7); Activity, 12 (7) and QoL, 10 (7). PAH treatment resulted in significant improvements in CAMPHOR scores (p < 0.05). CAMPHOR MCIDs averaged across methods for health status improvement were: Symptoms, -4 points; Activity, -4 points and QoL -3 points. CAMPHOR Activity score change >= MCID with PAH treatment was associated with significantly greater improvement in 6-minute walk distance, in both discovery and validation cohorts. In conclusion, CAMPHOR scores are responsive to improvements in functional capacity with PAH treatment. MCIDs in PAH scales may provide useful insights into treatment response in future clinical trials.

show abstract

“…HRQoL was assessed by self‐administering questionnaires. Participants were asked to complete the Portuguese validated version of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) questionnaire, an HRQoL instrument specific to PAH patients, validated for use in clinical practice and in clinical research settings 12 …”

Section: Methodsmentioning

confidence: 99%

Physical activity and its clinical correlates in chronic thromboembolic pulmonary hypertension

et al. 2022

Self Cite

View full text Add to dashboard Cite

Limited data are available on physical activity (PhA) levels in chronic thromboembolic pulmonary hypertension (CTEPH) patients, as well as on the clinical utility of PhA measurements using questionnaires and accelerometers.We aimed to study PhA levels of CTEPH patients and their clinical correlates, and to compare PhA levels measured by the International Physical Activity Questionnaire (IPAQ) with measures from accelerometers. This is a crosssectional study (n = 50). PhA levels were measured using accelerometers and questionnaires (IPAQ). Clinical parameters evaluated were walked distance on the 6-min-walking test (6MWT), pulmonary vascular resistance, N-terminal brain natriuretic peptide and quality of life (HRQoL) (Cambridge Pulmonary Hypertension Outcome Review questionnaire). Time spent in sedentary behavior was lower in self-reported measurement (279 ± 165 min/day) compared with accelerometry (446 ± 117 min/day, p < 0.000). Accelerometer-derived data showed that CTEPH patients spent 60% of the recorded time in sedentary behaviors and 2% in moderate-to-vigorous PhA (MVPA). Correlation analysis showed that MVPA was significantly correlated with 6MWT (p = 0.023) and symptom domain of HRQoL (p = 0.044). Self-reported MVPA was significantly higher than the one registered by the accelerometer (411 ± 569 vs. 131 ± 108 min/week, p = 0.027). Bland−Altman analysis indicated poor agreement between the two methods. Our results showed that CTEPH patients spend most of their days in sedentary behaviors and only a small amount of time in MVPA. Only MVPA was associated with HRQoL and CTEPH severity. In addition, we showed a poor agreement between selfreported and accelerometer-derived PhA in CTEPH patients, with the former overestimating the overall PhA.

show abstract

Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire

Cited by 8 publications

References 36 publications

Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study

Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study

A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension

Physical activity and its clinical correlates in chronic thromboembolic pulmonary hypertension

Contact Info

Product

Resources

About